Re: ZEN-3694 Single Agent Trial Status
in response to
by
posted on
Sep 18, 2017 11:17PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Anyone want to make bets on which company announces a deal first. Zenith or RVX? Or, is there a deal for both companies announced?
I say Zenith first.
This is just speculation.
tada